We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

230 hedge funds and large institutions have $789M invested in Xeris Biopharma Holdings in 2025 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 77 increasing their positions, 61 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

396% more call options, than puts

Call options by funds: $3.88M | Put options by funds: $782K

111% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 28

87% more capital invested

Capital invested by funds: $422M → $789M (+$366M)

26% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 61

15% more funds holding

Funds holding: 200 → 230 (+30)

2.14% more ownership

Funds ownership: 57.85% → 59.99% (+2.1%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
230
Holders Change
+30
Holders Change %
+15%
% of All Funds
3.02%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
59
Increased
77
Reduced
61
Closed
28
Calls
$3.88M
Puts
$782K
Net Calls
+$3.1M
Net Calls Change
+$2.46M

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$13.3M
2
UBS Group
UBS Group
Switzerland
+$10.3M
3
Jane Street
Jane Street
New York
+$5.86M
4
Charles Schwab
Charles Schwab
California
+$5.84M
5
Deutsche Bank
Deutsche Bank
Germany
+$5.52M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$16M
2
CP
CenterBook Partners
Connecticut
-$5.95M
3
CSS
Cubist Systematic Strategies
Connecticut
-$4.11M
4
Goldman Sachs
Goldman Sachs
New York
-$3.16M
5
Legal & General Group
Legal & General Group
United Kingdom
-$2.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
AL
151
Aspiriant LLC
California
$163K +$133K +20,000 New
TI
152
Tidal Investments
Wisconsin
$159K +$129K +19,485 New
AIM
153
Aigen Investment Management
New York
$156K +$127K +19,129 New
N
154
Numerai
California
$151K +$123K +18,507 New
Los Angeles Capital Management
155
Los Angeles Capital Management
California
$146K -$16.5K -2,481 -12%
MWM
156
Modern Wealth Management
Kansas
$144K – – –
QCM
157
Quantinno Capital Management
New York
$144K +$34K +5,123 +41%
Rafferty Asset Management
158
Rafferty Asset Management
New York
$142K -$56.4K -8,492 -33%
QC
159
Quadrature Capital
United Kingdom
$141K -$196K -29,467 -63%
Victory Capital Management
160
Victory Capital Management
Texas
$140K -$2.35K -353 -2%
PAP
161
Persistent Asset Partners
Hong Kong
$140K +$114K +17,202 New
Capstone Investment Advisors
162
Capstone Investment Advisors
New York
$139K +$114K +17,130 New
SFI
163
Susquehanna Fundamental Investments
Pennsylvania
$139K – – –
JWM
164
Jacksonville Wealth Management
Florida
$138K +$113K +17,000 New
CBU
165
CIBC Bancorp USA
Illinois
$133K +$109K +16,367 New
AAP
166
Arax Advisory Partners
Colorado
$129K +$105K +15,859 New
LCM
167
Landscape Capital Management
New Jersey
$128K – – –
VPIM
168
Vanguard Personalized Indexing Management
California
$127K +$103K +15,561 New
PCM
169
Prelude Capital Management
New York
$126K – – –
AI
170
Atom Investors
Texas
$122K -$21.2K -3,187 -18%
VC
171
Veery Capital
Delaware
$115K – – –
EWM
172
Empirical Wealth Management
Washington
$111K – – –
Universal-Beteiligungs- und Servicegesellschaft
173
Universal-Beteiligungs- und Servicegesellschaft
Germany
$107K +$87.4K +13,155 New
SOW
174
State of Wyoming
Wyoming
$105K -$148K -22,306 -63%
AIP
175
Ameritas Investment Partners
Nebraska
$104K -$9.15K -1,378 -10%
5 6
7
8 9

XERS Hedge Fund Activity: Q3 2025 in Review

230 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2025, worth a combined $789M — up 87% from $422M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new XERS positions and 28 closed out — a net gain of 31 holders — while 77 added to existing stakes and 61 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $13.3M. The largest seller was Millennium Management, cutting an estimated $16M.

  • 230 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2025, up from 200 in Q2 2025.
  • Funds reported $789M of Xeris Biopharma Holdings stock for Q3 2025, up 87% quarter-over-quarter.
  • 59 funds opened new Xeris Biopharma Holdings positions in Q3 2025 and 28 closed out, a net change of +31 holders.
  • The largest Xeris Biopharma Holdings buyer in Q3 2025 was D.E. Shaw & Co, an estimated $13.3M added.
  • The largest Xeris Biopharma Holdings seller in Q3 2025 was Millennium Management, an estimated $16M sold.

Based on aggregated 13F filings for Q3 2025.